Review Article | Published:

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor

Nature Clinical Practice Rheumatology volume 2, pages 602610 (2006) | Download Citation

Subjects

Abstract

Tumor necrosis factor (TNF) is a proinflammatory cytokine that has a key role in the pathogenesis of a variety of autoimmune diseases—including rheumatoid arthritis—and is an important constituent of the human immune response to infection. At present, three anti-TNF agents are approved (in the US and elsewhere) to treat selected autoimmune diseases: infliximab, etanercept, and adalimumab. These biologic agents have been associated with a variety of serious and 'routine' opportunistic infections; however, differences exist in the mechanisms of action of these agents that might confer variation in their associated risks of infection. From a public-health standpoint, the development of active tuberculosis in some patients who receive anti-TNF therapy is a matter of serious concern. Tuberculosis in such patients frequently presents as extrapulmonary or disseminated disease, and clinicians should be vigilant for tuberculosis in any patient taking anti-TNF therapy who develops fever, weight loss, or cough. To prevent the reactivation of latent tuberculosis infection during anti-TNF therapy, clinicians should screen all patients for tuberculosis, and begin treatment if latent infection is found, before anti-TNF therapy is initiated. Specific tuberculosis screening and treatment strategies vary between geographical regions and are reviewed in this document. The screening strategies employed in Europe and North America have reduced the occurrence of anti-TNF-associated tuberculosis and are clearly to be recommended, but the role of screening in the prevention of other opportunistic (e.g. fungal) infections is far less certain.

Key points

  • A variety of infections have been reported in association with the use of tumor necrosis factor (TNF) antagonists; among these, the development of tuberculosis is of serious concern

  • Clinicians should be vigilant for tuberculosis in any patient taking anti-TNF therapy who develops fever, constitutional symptoms, or cough; in this setting, tuberculosis often manifests as extrapulmonary or disseminated disease

  • Screen patients for risk factors for Mycobacterium tuberculosis and test them for infection before initiating immunosuppressive therapies, including TNF antagonists

  • Latent tuberculosis infection should be treated in accordance with local guidelines

  • Interferon gamma release assays might also be used to test for latent tuberculosis infection, although experience of using these assays in immunosuppressed populations is limited

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. (2005) Updated consensus statement on biological agents, specifically tumour necrosis factor-α (TNF-α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 64 (Suppl 4): iv2–iv14

  2. 2.

    et al. (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48: 3013–3022

  3. 3.

    et al. (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84: 291–302

  4. 4.

    et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261–1265

  5. 5.

    et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. [Erratum] Clin Infect Dis 39: 1254–1255

  6. 6.

    et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 345: 1098–1104

  7. 7.

    Centers for Disease Control and Prevention (CDC) (2004) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002–2003. MMWR Morb Mortal Wkly Rep 53: 683–686

  8. 8.

    et al. (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39: 295–299

  9. 9.

    et al. (2005) Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 52: 2968–2974

  10. 10.

    British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60: 800–805

  11. 11.

    et al. (2005) British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology (Oxford) 44: 1205–1206

  12. 12.

    (2000) Tumor necrosis factor: biology and therapeutic implications. Gastroenterology 119: 1148–1157

  13. 13.

    (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41 (Suppl 3): S199–S203

  14. 14.

    et al. (2003) Tumor necrosis factor signaling. Cell Death Differ 10: 45–65

  15. 15.

    et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561–572

  16. 16.

    et al. (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 (Suppl 3): S189–S193

  17. 17.

    et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620–4627

  18. 18.

    et al. (1989) The inducing role of tumor necrosis factor in the development of bactericidal gramulomas during BCG infection. Cell 56: 731–740

  19. 19.

    et al. (2001) Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting patholology. Infect Immun 69: 1847–1855

  20. 20.

    et al. (2001) TNF-α controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 166: 6728–6734

  21. 21.

    et al. (1995) Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 63: 4862–4867

  22. 22.

    et al. (1998) Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol 161: 2383–2390

  23. 23.

    et al. (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798–802

  24. 24.

    (2005) Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 41 (Suppl 3): S204–S207

  25. 25.

    et al. (1999) Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun 67: 595–601

  26. 26.

    et al. (2005) Defective innate antibacterial host responses during murine Klebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with anti-TNF-alpha. Clin Infect Dis 41 (Suppl 3): S213–S217

  27. 27.

    et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301: 418–426

  28. 28.

    and (2003) Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 168: 1153–1156

  29. 29.

    Canadian Pharmacists Association (2002) Remicade (infliximab) Schering Canada [product monograph]. In Compendium of pharmaceuticals and specialties, 1443. Toronto: Webcom Ltd

  30. 30.

    Canadian Pharmacists Association (2002) Enbrel (etanercept) Wyeth-Ayerst [product monograph]. In Compendium of pharmaceuticals and specialties, 569. Toronto: Webcom Ltd

  31. 31.

    et al. (2003) Infliximab but not etancercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124: 1774–1785

  32. 32.

    et al. (2005) Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251–258

  33. 33.

    et al. (2001) Infliximab induces apotosis in monocytes from patient with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145–1157

  34. 34.

    et al. (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22–28

  35. 35.

    et al. (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088–1094

  36. 36.

    et al. (2006) Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 18: 25–32

  37. 37.

    et al. (2005) Treatment of sarcoidosis with infliximab. Chest 127: 1064–1071

  38. 38.

    et al. (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52: 61–72

  39. 39.

    et al. (2005) Differential effects of tumor necrosis factor blockers on mycobacterial immunity in vitro [abstract]. Arthritis Rheum 52 (Suppl): S274

  40. 40.

    et al. (2003) The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76–85

  41. 41.

    World Health Organization (online March 2006) Fact sheet no. 104: tuberculosis [] (Accessed 15 September 2006)

  42. 42.

    et al. (2003) Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 3: 578–590

  43. 43.

    et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3: 148–155

  44. 44.

    et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 345: 1098–1104

  45. 45.

    et al. (1990) Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 141: 347–351

  46. 46.

    FDA briefing document (online 4 March 2003) Update on the TNF-α blocking agents. [.] (accessed 15 September 2006)

  47. 47.

    et al. (2005) Impact of screening for latent TB prior to initiation anti-TNF therapy in North America and Europe. Ann Rheum Dis 64 (Suppl III): 86

  48. 48.

    et al. (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 (Suppl 3): S194–S198

  49. 49.

    et al. (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52: 3403–3412

  50. 50.

    et al. (2005) Influence of bacillus Calmette–Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 40: 211–217

  51. 51.

    Centers for Disease Control and Prevention (1997) Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations. MMWR Recomm Rep 46 (RR-15): 1–10

  52. 52.

    American Thoracic Society (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161 (Pt 2): S221–S247

  53. 53.

    et al. (2004) Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 4: 761–776

  54. 54.

    et al. (2005) Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (RR-15): 49–55

  55. 55.

    et al. (2006) Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194: 479–485

  56. 56.

    et al. (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50: 372–379

  57. 57.

    et al. (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52: 1766–1772

  58. 58.

    et al. (2002) Infectious Disease Society of America. Guidelines for preventing opportunisitic infections among HIV-infected persons—2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51 (RR-8): 1–52

  59. 59.

    et al. (2003) Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis 5: 3–8

  60. 60.

    et al. (2004) Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50: 1959–1966

  61. 61.

    US Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program [] (accessed 15 September 2006)

  62. 62.

    Centers for Disease Control and Prevention (CDC) and American Thoracic Society (2003) Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection—United States, 2003. MMWR Morb Mortal Wkly Rep 52: 735–739

  63. 63.

    American Thoracic Society (CDC) and Infectious Diseases Society of America (2003) Treatment of tuberculosis. MMWR Recomm Rep 52 (RR-11): 1–77

Download references

Acknowledgements

The author gratefully acknowledges the assistance of Dr Jeff Siegel who provided a critical review of this manuscript.

Author information

Affiliations

  1. KL Winthrop is an Assistant Professor in the Division of Infectious Diseases, Department of Medicine, and in the Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland, OR, USA.

    • Kevin L Winthrop

Authors

  1. Search for Kevin L Winthrop in:

Competing interests

The author declares no competing financial interests.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncprheum0336

Further reading